Rida Mourtada is a co-founder and Chief Executive Officer at Lytica Therapeutics, a biotechnology company focused on developing novel therapeutics to treat infectious diseases and cancer. He has over a decade of research experience in the preclinical development of peptide therapeutics.
Rida has co-invented several peptide platform technologies including Lytica’s Stapled Peptide Antimicrobial Peptide (StAMP)and Stapled Peptide Antibody Conjugate Engineering (SPACE) platforms. Rida received his doctorate from the Harvard-MIT Program in Health Sciences and Technology at MIT and completed his bachelor’s and master’s degrees at the University of Toronto, Canada.